🔎 Trials Near Me

홈 › 전이성 암 › 네브래스카

네브래스카의 전이성 암 임상 시험

전이성 암 관련 연구 16개가 네브래스카 내 여러 지역에서 참여자를 모집하고 있습니다.

네브래스카의 도시

공식 연구 텍스트(영어)

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

  • Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT07007559

Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  • University of Nebraska Medical Center, Omaha
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT07562152

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  • University of Nebraska Medical Center, Omaha
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06943755

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens

  • Nebraska Methodist Hospital, Omaha
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT06127407

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT06769698

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  • Nebraska Medicine, Omaha
  • Nebraska Medicine - Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT06989437

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • NHO Revive Research Institute, LLC, Lincoln
  • NHO Support Center, Lincoln
  • Cancer Partners of Nebraska, Lincoln
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07222566

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  • Cancer Partners of Nebraska, Lincoln
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT07222800

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

  • Research Site, Omaha
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT07205822

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • Nebraska Cancer Specialists, Omaha
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07277413

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

  • Nebraska Cancer Specialists, Omaha
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT06072612

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

  • Nebraska Methodist Hospital, Omaha
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 6. 16. 업데이트됨 · NCT05208047

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
  • XCancer Omaha / Urology Cancer Center, Omaha
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 11. 업데이트됨 · NCT05283330

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

  • Nebraska Cancer Specialists, Omaha
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 2. 18. 업데이트됨 · NCT07030257

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774

A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors

  • Nebraska Cancer Specialists (NCS), Omaha
피험자 모집 중1상
18세 이상 · 모든 성별 · 2024. 11. 7. 업데이트됨 · NCT06190886

ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.